Clinical Trials
22 trialsNCT03789097 2026-05-22
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT03739931 2025-08-15
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
ModernaTX, Inc.
Phase 1 Completed
NCT03894618 2025-04-02
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
Phase 1 Completed
NCT02783300 2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1 Completed
NCT03674567 2025-01-24
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
RAPT Therapeutics, Inc.
Phase 1/2 Completed
NCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
NCT03454451 2023-12-21
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
Phase 1 Completed
NCT03229278 2023-12-06
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT02797964 2023-06-18
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
Sierra Oncology LLC - a GSK company
Phase 1/2 Completed
NCT00002520 2023-06-15
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Eastern Cooperative Oncology Group
Phase NA Completed
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT01353625 2021-10-05
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Celgene
Phase 1 Completed
NCT03212157 2021-09-29
GlucoCEST MRI in Oncology
University College, London
Phase NA Completed
NCT00963911 2021-04-05
ONCODAGE
Institut Bergonié
Phase NA Completed
NCT03538028 2020-10-30
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT01307267 2020-03-17
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Pfizer
Phase 1 Completed
NCT00835341 2015-06-01
Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia
Peking University
Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00004065 2013-06-24
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00045006 2013-05-30
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00020579 2012-03-15
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00049296 2010-06-11
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Phase 1 Completed